EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY 4.0

Impact of renal impairment on pharmacokinetics, safety, and tolerability of funobactam, combined with imipenem and cilastatin

Keith A Rodvold iD, Grigor Mamikonyan, Yu Wang, Anastasia McRoberts, Dyal Garg, Richard Preston, Thomas Marabury, Meijie Le, Jianguo Li iD

Antimicrobial Agents and Chemotherapy · 07.10.2026 · 70 (10)

DOI: 10.1128/aac.00808-26 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 07.10.2026. Verfasst von Keith A Rodvold und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Illinois Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Cilastatin, Cilastatin, Imipenem Drug Combination, Imipenem. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Evopoint Biosciences USA, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A phase 1, open-label study was conducted to investigate the effect of renal impairment (RI) on pharmacokinetics (PK) and safety of funobactam plus imipenem/cilastatin. Participants were enrolled and assigned to one of five cohorts based on renal function category: normal renal function, mild RI, moderate RI, severe RI, and end-stage renal disease (ESRD) requiring hemodialysis (HD). Participants received a single-dose of funobactam with imipenem and cilastatin by intravenous infusion administered over 60 min. Serial blood and urine samples were collected for non-compartmental PK analysis. Compared to participants with normal renal function, the geometric mean ratio (90% confidence interval) of plasma area under the curve (AUC0-∞) for funobactam, imipenem, and cilastatin increased with RI from mild (1.32 [1.04, 1.66], 1.37 [1.04, 1.79], and 1.27 [0.90, 1.78], respectively) to ESRD requiring HD (9.58 [7.59, 12.10], 2.69 [2.06, 3.52], and 15.15 [10.8, 21.3], respectively). The renal clearance for funobactam, imipenem, and cilastatin decreased progressively from normal renal function (3.93 ± 1.12 L/h, 4.95 ± 2.40 L/h, and 6.98 ± 2.75 L/h, respectively) to severe RI (0.94 ± 0.37 L/h, 1.16 ± 0.34 L/h, and 1.70 ± 0.60 L/h, respectively). Plasma clearance of funobactam, imipenem, and cilastatin correlated (r ≥0.93) with creatinine clearance and the estimated glomerular filtration rate. The treatment was well tolerated, with no deaths, severe adverse events, or discontinuation due to adverse events. Dosage adjustments of funobactam, imipenem, and cilastatin will be needed in patients with renal impairment or ESRD requiring HD. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT04787562 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsCilastatinCilastatin, Imipenem Drug CombinationImipenemRenal InsufficiencyAdultAgedFemaleHumansMaleMiddle AgedArea Under CurveKidney Failure, Chronic

Stichwörter der Autor:innen

XNW4107cilastatinfunobactamimipenempharmacokineticsrenal impairmentsafety

Substanzen

Anti-Bacterial AgentsCilastatinCilastatin, Imipenem Drug CombinationImipenem

Autor:innen und Institutionen

  • University of Illinois Chicago, Chicago, Illinois, USA.
  • Clinartis LLC, Hollywood, Florida, USA.
  • Evopoint Biosciences Co Ltd, Suzhou, China.
  • Pharmaron Germantown, Germantown, Maryland, USA.
  • Clinical Research Services Inc., Boynton Beach, Florida, USA.
  • Division of Clinical Pharmacology, University of Miami, Miami, Florida, USA.

ORCID-Profile: Keith A Rodvold, Jianguo Li

Förderung

  • Evopoint Biosciences USA, Inc.

Zitieren

APA

Rodvold, K. A., Mamikonyan, G., Wang, Y., McRoberts, A., Garg, D., Preston, R., Marabury, T., Le, M., & Li, J. (2026). Impact of renal impairment on pharmacokinetics, safety, and tolerability of funobactam, combined with imipenem and cilastatin. Antimicrobial Agents and Chemotherapy, 70(10). https://doi.org/10.1128/aac.00808-26

Vancouver

Rodvold KA, Mamikonyan G, Wang Y, McRoberts A, Garg D, Preston R, et al. Impact of renal impairment on pharmacokinetics, safety, and tolerability of funobactam, combined with imipenem and cilastatin. Antimicrobial Agents and Chemotherapy. 2026;70(10). doi:10.1128/aac.00808-26

BibTeX
@article{Rodvold2026,
  author = {Rodvold, Keith A and Mamikonyan, Grigor and Wang, Yu and McRoberts, Anastasia and Garg, Dyal and Preston, Richard and Marabury, Thomas and Le, Meijie and Li, Jianguo},
  title = {Impact of renal impairment on pharmacokinetics, safety, and tolerability of funobactam, combined with imipenem and cilastatin},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {10},
  doi = {10.1128/aac.00808-26}
}
Kostenlos starten →